2 days ago
Medtech leaders unite on Capitol Hill to fight tariffs
Amid ongoing trade policy debates, leaders from the medtech industry convened on Capitol Hill alongside the Advanced Medical Technology Association (AdvaMed) to advocate for the elimination of tariffs on medical technologies.
Senior executives from medtech giants including GE HealthCare, Roche Diagnostics, and Karl Storz participated in the June 11 initiative, signaling a unified industry stance on key policy priorities.
In a LinkedIn post spotlighting the advocacy efforts in Washington, D.C., Roland Rott, President & CEO of Imaging at GE HealthCare, called for policy reforms that spur innovation and expand access to care.
Highlighting the need for actionable change, Rott stated that healthcare must remain a strategic priority 'not just in rhetoric, but through meaningful policy decisions.'
Rott was joined by prominent industry leaders, including Peter Arduini, CEO of GE HealthCare; Brad Moore, CEO of Roche Diagnostics North America; Sonal Matai, US leader at Karl Storz; John Kowal, head of Siemens Healthineers Americas; Scott Whitaker, CEO of AdvaMed; and Roxy Kozycky, Senior Director at AdvaMed.
The leaders called for several core policy changes: "zero for zero" tariffs on medical technologies, modernised reimbursement models that include AI innovations, and strong protections for public research funding and global scientific collaboration.
The recommendations come amid significant concern from the US medtech industry over President Trump's recent tariff policies, particularly those targeting imports from China, Canada, and Mexico. Industry leaders have warned that the tariffs could disrupt supply chains, increase costs, and hinder innovation.
In the near term, the full impact of US government tariffs on the medtech sector remains uncertain. GlobalData analysis indicates that healthcare facilities may begin to stock up on medical devices to prepare for increased pricing.
Manufacturers such as Medtronic have adopted a strategic approach and expanded their US-based production to reduce any negative impact on their financial outlook.
Analysts speculate that if the tariffs can be supported by pro-manufacturing policies, they could encourage the re-shoring of medtech production and potentially drive new investments in US-based supply chains and startups.
"Medtech leaders unite on Capitol Hill to fight tariffs" was originally created and published by Medical Device Network, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
